DrugPatentWatch Database Preview
LIPIODOL Drug Profile
» See Plans and Pricing
When do Lipiodol patents expire, and what generic alternatives are available?
Lipiodol is a drug marketed by Guerbet and is included in one NDA.
The generic ingredient in LIPIODOL is ethiodized oil. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ethiodized oil profile page.
Summary for LIPIODOL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 34 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for LIPIODOL |
| What excipients (inactive ingredients) are in LIPIODOL? | LIPIODOL excipients list |
| DailyMed Link: | LIPIODOL at DailyMed |
Generic Entry Opportunity Date for LIPIODOL
Generic Entry Date for LIPIODOL*:
Constraining patent/regulatory exclusivity:
SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC) NDA:
Dosage:
OIL;INTRALYMPHATIC, INTRAUTERINE |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LIPIODOL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Dafne Balemans | Phase 4 |
| Memorial Sloan Kettering Cancer Center | Phase 1 |
| Assiut University | Early Phase 1 |
US Patents and Regulatory Information for LIPIODOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guerbet | LIPIODOL | ethiodized oil | OIL;INTRALYMPHATIC, INTRAUTERINE | 009190-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
